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r. Perez-Moreno is fundehe purpose of this study was to examine the relationship between fatigue and clinical outcomes, using dyspnea as
a comparator, in patients with left ventricular ejection fraction (LVEF) 35% enrolled in the CORONA (Controlled
Rosuvastatin Multinational Trial in Heart Failure) study.Background Although fatigue is a common symptom in heart failure (HF), little is known about its association with prognosis.Methods At baseline in CORONA, fatigue “during the past few days” was measured using a 5-point exertion scale (0 ¼ none,
1 ¼ heavy exertion, 2 ¼ moderate exertion, 3 ¼ slight exertion, 4 ¼ rest); a 4-point scale was used for dyspnea
(1 to 4 as for fatigue). Patients were grouped into 3 categories: a fatigue score 0 to 1 (n ¼ 535), fatigue score
2 (n ¼ 1,632), and fatigue score 3 to 4 (n ¼ 1,663); and a dyspnea score of 1 (n ¼ 292), dyspnea score of
2 (n ¼ 1,695), and dyspnea score of 3 to 4 (n ¼ 1,843). The association between fatigue and dyspnea and the
composite outcome of cardiovascular (CV) death or HF hospital stay and each component separately was examined
using Kaplan-Meier analysis and Cox proportional-hazard models. We also examined all-cause mortality.Results In univariate analyses, symptom severity was associated with a higher risk of CV death or HF hospital stay (fatigue:
group 3, 49% [n ¼ 810], vs. group 1, 30% [n ¼ 160]; dyspnea: group 3, 50% [n ¼ 918], vs. group 1, 28% [n ¼ 82])
and all-cause mortality (fatigue: group 3, 38% [n ¼ 623], vs. group 1, 24% [n ¼ 130]; dyspnea: group 3, 38%
[n ¼ 697], vs. group 1, 23% [n ¼ 66], log-rank p < 0.0001 for all). After adjusting for other prognostic variables,
including LVEF, New York Heart Association class, and N-terminal pro-B-type natriuretic peptide level, worse fatigue
remained associated with higher risk of HF hospital stay but not mortality (worse dyspnea remained associated with
a higher risk of both). An increase in fatigue (or dyspnea) between baseline and 6 months was also associated with
worse outcomes.Conclusions In HF, greater fatigue is associated with worse clinical outcomes. Closer attention should be paid to this symptom in
clinical practice, with more done to standardize its measurement and understand its origins, with a view to improving
treatment. (J Am Coll Cardiol HF 2014;2:187–97) ª 2014 by the American College of Cardiology FoundationAlthough dyspnea is the best recognized symptomatic
manifestation of heart failure (HF), fatigue is also a proto-
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188had not experienced this symptom
at all. Of those reporting fatigue,
53% experienced the symptom at
least once a day (3). Similar ﬁnd-
ings have been reported in other
studies (4,5). Despite the preva-
lence of fatigue in HF, the cause
of this symptom is uncertain and
contentious (6–10). It has even
been argued that both fatigue and
the other cardinal symptom of
HF, dyspnea, have a common
origin (7,10). Even less is knownabout the prognostic importance of fatigue (and change in
fatigue) in patients with chronic HF, and these questions were
the focus of this study (11).
We examined the prevalence and severity of fatigue (and
dyspnea for comparison) at baseline in the CORONA
(Controlled Rosuvastatin Multinational Trial in Heart
Failure) study and whether these symptoms were predictors
of outcome (12). We also examined the relationship between
change in fatigue (and dyspnea) from baseline to outcomes.
Methods
A total of 5,011 patients age 60 years with symptomatic
(New York Heart Association [NYHA] class II to IV), sys-
tolic (left ventricular ejection fraction [LVEF] 40% but no
more than 35% in patients with NYHA class II) HF of
ischemic origins were enrolled in CORONA. Patients were
randomized to receive 10 mg of rosuvastatin or matching
placebo once daily (12,13). The ethics committee at each of
the participating hospitals approved the trial, and patients
provided written informed consent. The primary composite
outcome was death from cardiovascular (CV) causes, nonfatal
myocardial infarction, or nonfatal stroke. The median follow-
up was 32.8 months. Compared with placebo, rosuvastatin
did not reduce the primary outcome or death from any cause.
Fatigue “during the past few days” was measured using a
5-point exertion scale (0 ¼ none, 1 ¼ heavy exertion,
2¼ moderate exertion, 3¼ slight exertion, 4¼ rest) recorded
by the investigator. Dyspnea “during the past few days”
was measured using a 4-point exertion scale (1 ¼ heavy exer-
tion, 2 ¼ moderate exertion, 3 ¼ slight exertion, 4 ¼ rest); a
4- rather than 5-point scale was used for dyspnea because the
presence of dyspnea at baseline was an inclusion criterion for
CORONA. These symptoms were measured at baseline and
at 6 and 12 weeks after randomization and every 3 months
thereafter.
Only patients with LVEF 35% (n ¼ 3,830) were
included in the current analyses because patients with LVEF
>35% (and 40%) had to be in NYHA class III or IV; we
wished to examine the predictive value of fatigue and dys-
pnea in addition to NYHA functional class.
Patients were grouped into 3 categories at baseline in
order to provide sufﬁcient numbers for analysis in eachcategory (see Results): fatigue score 0 to 1 and 2 and 3 to 4;
dyspnea score 1 and 2 and 3 to 4. We also examined change
in fatigue from baseline to the 6-month visit, classifying
patients as showing a decrease (reduction in score), an in-
crease (an increase in score), or no change (unchanged score)
in symptoms.
Statistical analyses. Baseline characteristics are presented
as mean  SD symptom group at baseline for continuous
variables and percent for categorical variables. Baseline
characteristics were compared across groups, using one-way
analysis of variance for continuous variables and the chi-
square test for categorical variables.
We tested the prognostic value of each symptom relative
to the composite outcome of CV death or hospital stay
due to worsening HF, using Cox proportional hazard
regressionmodels. CVdeath or hospital stay due to worsening
HF rather than the prespeciﬁed primary outcome of
CORONAwas used in the present analysis as it better reﬂects
disease-speciﬁc morbidity and mortality related to HF (and
the primary endpoint of CORONA was recommended by
regulatory authorities to reﬂect the treatment intervention
used, e.g., a statin) (14,15). Other outcomes analyzed were the
components of the composite (CV death andHFhospital stay
individually) and all-cause death. The covariates used were on
the basis of previously reported predictive models (age, sex,
NYHA class, LVEF, bodymass index [kg/m2], systolic blood
pressure, heart rate, smoking, myocardial infarction, angina
pectoris, coronary artery bypass graft, percutaneous coronary
intervention, aortic aneurysm, hypertension, diabetes, base-
line atrial ﬁbrillation/ﬂutter, stroke, intermittent claudication,
pacemaker, implantable cardioverter-deﬁbrillator, apolipo-
protein A-1, apolipoprotein B, creatinine, alanine amino-
transferase, creatine kinase, triglycerides, C-reactive protein,
high-density lipoprotein, low-density lipoprotein, estimated
glomerular ﬁltration rate, and N-terminal prohormone of
brain natriuretic peptide [NT-proBNP]) (16). A logarithmic
transformation of NT-proBNPwas performed. Linearity and
proportional hazard assumptions were assessed for all model
covariates.
Kaplan-Meier cumulative event curves are presented by
symptom category and compared with log-rank tests. Similar
analyses were carried out that examined the relationship
between change in symptoms (baseline to 6 months) and
subsequent clinical outcomes (from 6 months to the end of
the study). All p values reported are two-sided and a value
of <0.05 was considered statistically signiﬁcant. All statis-
tical analyses were performed using Stata version 12 (Stata
Corp, College Station, Texas).
Results
Of the 5,011 patients randomized, 3,830 (76%) had a
baseline LVEF 35%; all of them had a baseline measure
for dyspnea and fatigue. Figure 1 shows the distribution of
fatigue and dyspnea at baseline. Patients were grouped into 3
categories: those with fatigue scores 0 to 1 (n ¼ 535 [14%]),
Figure 1 Baseline Distribution of Symptoms
Symptoms of fatigue (blue) and dyspnea (red) are shown.
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1892 (n ¼ 1,632 [43%]) and 3 to 4 (n ¼ 1,663 [43%]); and with
dyspnea scores of 1 (n ¼ 292 [8%]), 2 (n ¼ 1,695 [44%]),
and 3 to 4 (n ¼ 1,843 [48%]).
Baseline characteristics, including comorbidities and
concomitant drug treatments, are summarized in Table 1.
Patients with higher levels of fatigue (i.e., fatigue on slight
exertion or at rest) were more likely to be older, female, and
have lower systolic blood pressure than patients with lower
levels of fatigue. They also had higher heart rates and were
more likely to be in NYHA functional class III or IV.
Patients with greater fatigue more frequently had a history
of myocardial infarction, hypertension, diabetes, atrial
ﬁbrillation or stroke, lower lipid levels, and estimated
glomerular ﬁltration rate, and higher levels of NT-proBNP
and high-sensitivity CRP. They were less likely to smoke.
Patients with higher levels of dyspnea (i.e., dyspnea at rest
or slight exertion) presented a generally similar pattern,
although there was no association between level of dyspnea
and history of stroke. The patients with both higher levels of
fatigue and dyspnea were more likely to be in atrial ﬁbrilla-
tion/ﬂutter at baseline and were more likely to be treated with
diuretic agents and digitalis. A cross-tabulation of numbers
with symptoms at baseline and between numbers with a
change in symptom severity at 6 months are presented in
Tables 2 and 3 respectively.
Clinical outcomes according to symptom severity at
baseline. UNADJUSTED OUTCOMES. Patients with higher
symptom severity were signiﬁcantly more likely to die from
any cause (fatigue group 3, n ¼ 623 [38%], vs. group 1,
n¼ 130 [24%]; dyspnea group 3, n¼ 697 [38%], vs. group 1,
n¼ 66 [23%]) and from CV causes (fatigue group 3, n¼ 501
[30%], vs. group 1, n¼ 104 [19%]; dyspnea group 3, n¼ 569
[31%], vs. group 1, n ¼ 52 [18%]). Those with greater
symptom severity were also more likely to be hospitalized for
worsening HF (fatigue group 3, n ¼ 559 [34%], vs. group 1,n ¼ 90 [17%]; dyspnea group 3, n ¼ 637 [35%], vs. group 1,
n ¼ 42 [14%]; log rank p < 0.0001 for all outcomes)
(Tables 4, 5, and 6, Figs. 2 and 3).
ADJUSTED OUTCOMES. Adjustment for the other variables
associated with worse clinical outcomes listed in Methods
(excluding NT-proBNP) weakened the relationship be-
tween symptom severity and death (group 3 vs group 1):
fatigue, CV death hazard ratio (HR) 1.18 (95% conﬁdence
interval [CI]: 0.92 to 1.52), p ¼ 0.20 and HF hospital
stay HR 1.54 (95% CI: 1.19 to 2.00), p ¼ 0.001
(Table 5); dyspnea, CV death HR 1.46 (95% CI: 1.04 to
2.07), p ¼ 0.03, and HF hospital stay HR 1.85 (95%
CI: 1.28 to 2.68), p ¼ 0.001 (Table 6). Fatigue and dys-
pnea continued to be predictive of the primary outcome
even when NT-proBNP level was considered (Figs. 4A
and 4B). However, adding NT-proBNP to the multivari-
able models slightly weakened the association between
severity of fatigue and death but not between fatigue
and HF hospital stay. Dyspnea at rest or slight exertion
continued to predict death as well as HF hospital stay
even after NT-proBNP was added to the multivariable
analyses.
Clinical outcomes according to change in symptom
severity between baseline and 6 months. UNADJUSTED
OUTCOMES. Of the 3,830 patients in this analysis, 3,548
(90.3%) had both a baseline and 6-month measure of fatigue
and dyspnea. Of these 3,548 patients, 712 (20.1%) reported
a decrease, 481 (13.6%) an increase, and 2,355 (66.4%) no
change in fatigue over that period. Those reporting an in-
crease in fatigue were signiﬁcantly more likely to die from
any cause and from a CV cause (Table 7). Patients reporting
an increase in fatigue were also less likely to be hospitalized
for worsening HF (Pearson chi-square test, p < 0.01 for
all outcomes) (Table 7). Of the 3,548 patients with both
a baseline and 6-month measure of dyspnea, 761 (21.5%)
reported a decrease, 367 (10.3%) an increase, and 2,420
(60.2%) no change in this symptom over that period. The
associations between change in dyspnea and outcomes were
similar to those observed for fatigue (Table 7).
ADJUSTED OUTCOMES. Adjustment for other variables
(including NT-proBNP level) weakened the relationship
between change in symptom severity and death (Table 8).
However, compared with those patients who exhibited no
change in symptoms, those with an increase in either
symptom had a higher HR for all outcomes (and the adjusted
HR for these outcomes was lower in patients reporting a
decrease in either fatigue or dyspnea) (Table 8). Patients
with an increase in fatigue had a signiﬁcantly higher risk of
the composite outcome of CV death or HF hospital stay
(HR: 1.35 [95% CI: 1.11 to 1.65]) and HF hospital stay
(HR: 1.55 [95% CI: 1.24 to 1.94]). The corresponding
ﬁndings for increase in dyspnea were: CV death or HF
hospital stay HR of 1.56 (95% CI: 1.26 to 1.92) and HF
hospital stay HR of 1.88 (95% CI: 1.50 to 2.37).
Table 1 Baseline Characteristics
All patients
Fatigue 1
(n ¼ 535)
Fatigue 2
(n ¼ 1632)
Fatigue 3
(n ¼ 1663) p Value
Dyspnea 1
(n ¼ 292)
Dyspnea 2
(n ¼ 1695)
Dyspnea 3
(n ¼ 1843) p Value
Age (yrs) 73.0  7.1 72.7  6.9 72.7  7.0 74.4  7.3 0.02 72.1  6.8 72.5  7.0 73.6  7.2 <0.01
Age 70 yrs 2,557 (66.7%) 351 (65.6%) 1,057 (64.8%) 1,149 (69.1%) 0.22 185 (63.4%) 1,091 (64.4%) 1,281 (69.5%) <0.01
Female 810 (21.2%) 80 (15%) 306 (18.8%) 424 (25.5%) <0.01 42 (14.4%) 320 (18.9%) 448 (24.3%) <0.01
Race
Caucasian 3,768 (98.4%) 529 (98.9%) 1,612 (98.8%) 1,627 (97.8%) 288 (98.6%) 1,672 (98.6%) 1,808 (98.1%)
Black 12 (0.3%) 2 (0.4%) 4 (0.3%) 6 (0.4%) 1 (0.3%) 5 (0.3%) 6 (0.3%)
Asian 34 (0.9%) 3 (0.6%) 5 (0.3%) 26 (1.56%) 3 (1.0%) 8 (0.5%) 23 (1.3%)
Other 16 (0.4%) 1 (0.2%) 11 (0.7%) 4 (0.2%) <0.01 0 (0%) 10 (0.6%) 6 (0.3%) 0.18
NYHA III/IV 2,001 (52.3%) 93 (17.4%) 529 (32.4%) 1,379 (82.9%) <0.01 17 (5.8%) 400 (23.6%) 1,584 (86.0%) <0.01
LVEF (%) 28.6  5.7 28.5  5.8 28.8  5.5 28.3  5.8 0.06 28.7  5.7 28.8  5.6 28.3  5.8 0.04
Systolic BP, mm Hg 128.5  16.9 129.8  17.7 129.6  16.6 127.1  16.7 <0.01 129.5  16.8 129.8  17.0 127.3  16.6 <0.01
Heart rate, beats/min 71.8  11.3 69.3  10.5 70.9  11.4 73.4  11.3 <0.01 68.3  10 70.6  11.3 73.4  11.3 <0.01
BMI, kg/m2 26.9  4.4 26.5  4 27.1  4.4 26.9  4.4 0.01 26.5  4 27.0  4.4 27.0  4.5 0.29
BMI > median (26.4 kg/m2) 1,900 (49.6%) 250 (46.7%) 839 (51.4%) 811 (51.4%) 0.05 132 (45.2%) 850 (50.1%) 918 (49.8%) 0.43
Current smoker 349 (9.1%) 67 (12.5%) 140 (8.6%) 142 (8.5%) 0.01 33 (11.3%) 161 (9.5%) 155 (8.4%) 0.21
Medical history
MI 2,311 (60.3%) 289 (54.0%) 987 (59.9%) 1,044 (62.8%) <0.01 149 (51.0%) 1,009 (59.5%) 1,153 (62.6%) <0.01
Angina pectoris 2,728 (71.2%) 313 (58.5%) 1,167 (71.5%) 1,248 (75.1%) <0.01 162 (55.5%) 1,176 (69.4%) 1,390 (75.4%) <0.01
CABG 694 (20.0%) 94 (19.8%) 323 (22.0%) 277 (18.1%) 0.03 50 (18.9%) 331 (21.8%) 313 (18.5%) 0.06
PCI/PTCA 1,052 (27.5%) 72 (13.5%) 221 (13.5%) 187 (11.2%) 0.11 37 (12.7%) 227 (13.4%) 216 (11.7%) 0.32
Hypertension 2,308 (60.3%) 261 (48.8%) 976 (59.8%) 1,071 (64.4%) <0.01 142 (48.6%) 1,008 (59.5%) 1,158 (62.8%) <0.01
Diabetes mellitus 1,109 (29.0%) 120 (22.4%) 452 (27.7%) 537 (32.3%) <0.01 60 (20.6%) 448 (26.4%) 601 (32.6%) <0.01
Baseline AF/F 895 (23.4%) 89 (16.6%) 345 (21.1%) 461 (27.7%) <0.01 39 (13.4%) 350 (20.7%) 506 (27.5%) <0.01
Stroke 478 (12.5%) 50 (9.4%) 175 (10.7%) 253 (15.2%) <0.01 26 (8.9%) 197 (11.6%) 255 (13.8%) 0.02
Pacemaker 454 (11.9%) 60 (11.2%) 188 (11.5%) 206 (12.4%) 0.66 22 (7.5%) 182 (10.7%) 250 (13.6%) <0.01
ICD 122 (3.2%) 24 (4.5%) 50 (3.1%) 48 (2.9%) 0.17 6 (2.1%) 59 (3.5%) 57 (3.1%) 0.42
Laboratory measurements
Cholesterol, mmol/l 5.3  1.1 5.4  1.0 5.4  1.0 5.3  1.1 0.01 5.4  1.0 5.4  1.0 5.3  1.1 <0.01
ApoB:ApoA-1 ratio 0.87  0.25 0.87  0.23 0.86  0.24 0.88  0.26 0.06 0.86  0.23 0.87  0.24 0.88  0.26 0.53
ApoB 1.27  0.30 1.28  0.29 1.27  0.29 1.26  0.31 0.50 1.26  0.27 1.28  0.29 1.26  0.31 0.05
ApoA-1 1.50  0.28 1.51  0.28 1.51  0.28 1.47  0.28 <0.01 1.51  0.26 1.51  0.27 1.48  0.29 0.01
Triglycerides, mmol/l 2.0  1.3 2.0  1.2 2.0  1.3 2.0  1.3 0.97 1.9  1.0 2.0  1.3 2.0  1.4 0.22
Serum creatinine, mmol/l 116.8  28.3 115.4  27.0 116.0  27.9 118.0  29.1 0.05 114.6  26.0 115.5  28.0 118.3  29.0 <0.01
Estimated GFR, ml/min/1.73 m2* 55.8  15.4 57.2  15.2 56.6  15.2 54.7  15.5 <0.01 57.5  14.5 57.0  15.4 54.5  15.4 <0.01
NT-proBNP, pmol/l (median) 193.8 140.5 178.3 232.2 <0.01 135.6 168.0 234.6 <0.01
hs-CRP, mg/l (median) 3.5 2.9 3.3 3.9 0.02 2.4 3.3 3.9 <0.01
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Table 2 Cross-Tabulation Between Symptoms at Baseline
Fatigue
Dyspnea
1 2 3/4 Total
0/1 219 238 78 535
2 57 1,245 330 1,632
3/4 16 212 1,435 1,663
Total 292 1,695 1,843 3,830
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191Various sensitivity analyses were performed (Online Tables).
Inclusion of all patients (i.e., those with LVEF between 36%
and 40%) and those receiving randomized treatment (i.e.,
placebo or rosuvastatin) in the adjusted models and use of a
more parsimonious adjusted model (top 10 predictive vari-
ables ranked by chi-square test) did not materially change the
results. When both fatigue and dyspnea were entered in the
predictive models together, the predictive value of each
symptom was diminished, moderately, for the primary com-
posite outcome.However, the strongest association of fatigue,
which was with HF hospital stay, was maintained qualita-
tively: level 3 versus 1 fatigue alone had an HR of 1.57 (95%
CI: 1.15 to 2.14; p¼ 0.01), and the fatigue plus dyspnea HR
was 1.37 (95% CI: 0.97 to 1.94; p ¼ 0.07). The association
between dyspnea and all-cause death was also maintained:
level 3 versus 1 dyspnea alone had an HR of 1.60 (95% CI:
91.08 to 2.37; p ¼ 0.02), and dyspnea plus fatigue HR was
1.61 (95% CI: 1.04 to 2.49; p ¼ 0.03).Discussion
We found the symptom of fatigue to be almost ubiquitous in
our trial, which enrolled only patients with symptoms (i.e.,
those inNYHA functional class II or greater andwith dyspnea
at baseline) and a reduced LVEF. Overall, only 5% of patients
reported no fatigue, and 9% reported fatigue only on severe
exertion. For most patients, fatigue was present on slight
(43%) or moderate (43%) exertion. The only other large trial
we know of which recorded fatigue was COMET (Carvedilol
Or Metoprolol European Trial), which used a 5-point scale,
although that scale was labeled differently (1¼ asymptomatic;
2 ¼ walking up stairs at normal pace; 3 ¼ walking at normal
pace on a ﬂat surface; 4 ¼ walking slowly on a ﬂat surface or
during washing or dressing; and 5 ¼ at rest). Few patientsTable 3
Cross-Tabulation Between Change in Symptoms
at 6 Months
Fatigue
Dyspnea
Decrease Increase Unchanged Total
Decrease 478 22 212 712
Increase 42 222 217 481
Unchanged 241 123 1,991 2,355
Total 761 367 2,420 3,548
Table 4 Clinical Outcomes According to Baseline Symptom Severity
Outcome
No. of Patients With Fatigue (%) No. of Patients With Dyspnea (%)
1
(n ¼ 535)
2
(n ¼ 1,632)
3
(n ¼ 1,663)
1
(n ¼ 292)
2
(n ¼ 1695)
3
(n ¼ 1,843)
CV death or HF hospital stay 160 (29.9) 598 (36.6) 810 (48.7) 82 (28.1) 568 (33.5) 918 (49.8)
CV death 104 (19.4) 356 (21.8) 501 (30.1) 52 (17.8) 340 (20.1) 569 (30.9)
HF hospital stay 90 (16.8) 391 (24.0) 559 (33.6) 42 (14.4) 361 (21.3) 637 (34.6)
All-cause death 130 (24.3) 452 (27.7) 623 (37.5) 66 (22.6) 442 (26.1) 697 (37.8)
CV ¼ cardiovascular; HF ¼ heart failure.
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192(<8%) were given the lowest or highest score on this scale,
although there was a more even distribution across the middle
3 scores in COMET than in CORONA, presumably
reﬂecting the different scale labeling, different patient char-
acteristics, or both. For example, patients in CORONA were
on average 10 years older than those in COMET and more
likely to have a history of myocardial infarction, hypertension,
or diabetes, and to be treated with beta-blockers at baseline;
they were less likely to be treated with angiotensin-converting
enzyme (ACE) inhibitors or diuretics.
We found that the baseline level of fatigue (as well as
dyspnea) was related to the primary composite endpoint
examined in the present analysis (CV death or HF hospital
stay), although this was driven by the HF hospital stay
component. This association was maintained after adjust-
ment for other known prognostic variables, including
NYHA class, LVEF, and NT-proBNP but was of border-
line signiﬁcance. Indeed, after adjustment, there was no
longer a statistically signiﬁcant association between fatigue
and CV mortality alone (or all-cause mortality), although the
association with HF hospital stay persisted. Interestingly,
and in contrast, the signiﬁcant relationship between dyspnea
and fatal outcomes persisted after adjustment, perhaps
questioning the view that these 2 symptoms are different
expressions of the same underlying disease mechanism or
mechanisms (7,17). If this were the case, it might be ex-
pected that both symptoms would predict outcomes in the
same manner and proportion.Table 5 Hazard Ratio for Fatigue Severity and Clinical Outcomes: Fa
Fatigue
Unadjusted
2 vs. 1 3 vs. 1
HR (95% CI) p Value HR (95% CI) p
CV death or HF
hospital stay
1.29 (1.08–1.53) 0.005 1.96 (1.65–2.32) <0
CV death 1.14 (0.92–1.42) 0.23 1.71 (1.39–2.12) <0
HF hospital stay 1.49 (1.19–1.88) 0.001 2.39 (1.91–2.98) <0
All-cause death 1.16 (0.95–1.41) 0.14 1.71 (1.41–2.06) <0
*Adjusted for age, sex, New York Heart Association class, left ventricular ejection fraction, body mass
coronary artery bypass graft, percutaneous coronary intervention, aortic aneurysm, hypertension, di
cardioverter-deﬁbrillator, ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, triglyceride
rate, and NT-proBNP.
CV ¼ cardiovascular; HF ¼ heart failure.Again, we know of only 1 other study testing whether
fatigue is an independent predictor of outcomes in HF. That
study was COMET (discussed earlier), and, in agreement
with our ﬁndings in CORONA, fatigue in COMET was a
predictor of death in unadjusted but not adjusted analyses.
Fatigue did, however, remain a predictor of HF hospital
stay after adjustment, as we also observed in CORONA,
although the model used in COMET contained fewer
variables and did not include NT-proBNP level. Curiously,
in COMET, dyspnea remained a predictor of death after
adjustment (as we found in CORONA) but not of HF
hospital stay (of which it remained strongly predictive of in
CORONA). The reason for this discrepancy is uncertain.
We also found that worsening of fatigue between baseline
and 6 months was predictive of worse outcomes, although,
once more, after adjustment, this association was most clear
cut for HF hospitalization. A similar relationship was seen
for worsening dyspnea. We do not believe that these ﬁnd-
ings have been reported before.
Why fatigue is predictive of clinical outcomes in HF is
unknown. It is easy to surmise that fatigue reﬂects muscle
hypoperfusion and is therefore a measure of diminished
cardiac output. However, this notion is probably too
simplistic. A skeletal myopathy may occur in HF and this,
in turn, may arise as a result of disturbed anabolic-catabolic
imbalance (10). Activation of metabolic or ergoreceptors
in muscle may also lead to sympathetic nervous system
activation, which is known to be detrimental in HF. Severitytigue
Adjusted*
2 vs. 1 3 vs. 1
Value HR (95% CI) p Value HR (95% CI) p Value
.001 1.12 (0.89–1.41) 0.34 1.28 (1.00–1.64) 0.05
.001 1.02 (0.76–1.36) 0.92 1.13 (0.82–1.54) 0.46
.001 1.29 (0.96–1.74) 0.10 1.57 (1.15–2.14) 0.01
.001 1.06 (0.82–1.38) 0.45 1.17 (0.89–1.55) 0.26
index, kg/m2, systolic blood pressure, heart rate, smoking, myocardial infarction, angina pectoris,
abetes, baseline atrial ﬁbrillation/ﬂutter, stroke, intermittent claudication, pacemaker, implant,
s, C-reactive protein, high-density lipoprotein, low-density lipoprotein, estimated glomerular ﬁltration
Table 6 Hazard Ratio for Fatigue Severity and Clinical Outcomes: Dyspnea
Dyspnea
Unadjusted Adjusted*
2 vs. 1 3 vs. 1 2 vs. 1 3 vs. 1
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
CV death or HF hospital stay 1.23 (0.98–1.55) 0.08 2.15 (1.72–2.70) <0.001 1.14 (0.84–1.55) 0.41 1.49 (1.07–2.08) 0.02
CV death 1.13 (0.84–1.51) 0.42 1.91 (1.44–2.54) <0.001 1.32 (0.87–2.02) 0.19 1.80 (1.15–2.81) 0.01
HF hospital stay 1.53 (1.11–2.11) 0.01 2.90 (2.12–3.97) <0.001 1.22 (0.82–1.82) 0.32 1.72 (1.12–2.62) 0.01
All-cause death 1.15 (0.89–1.49) 0.28 1.85 (1.44–2.38) <0.001 1.37 (0.96–1.97) 0.09 1.60 (1.08–2.37) 0.02
*Adjusted for age, sex, New York Heart Association class, left ventricular ejection fraction, body mass index kg/m2, systolic blood pressure, heart rate, smoking, myocardial infarction, angina pectoris,
coronary artery bypass graft, percutaneous coronary intervention, aortic aneurysm, hypertension, diabetes, baseline atrial ﬁbrillation/ﬂutter, stroke, intermittent claudication, pacemaker, implanted
cardioverter-deﬁbrillator, ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, triglycerides, C-reactive protein, high-density lipoprotein, low-density lipoprotein, estimated glomerular ﬁltration
rate, NT-proBNP.
CV ¼ cardiovascular; HF ¼ heart failure.
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193of fatigue is also related to depressive symptoms (3,18,19),
and depression is also an adverse prognostic ﬁnding in HF.
Whether there is a mechanistic link between fatigue, muscle
dysfunction, and depression (e.g., autonomic dysfunction) is
unknown. Fatigue in HF is also associated with anemia,
another adverse prognostic ﬁnding (20).Figure 2 Outcomes According to Symptom Severity
Fatigue 1, none or occurs upon heavy exertion; fatigue 2 occurs upon moderate exertion
CV death or HF hospital stay (A), CV death (B), HF hospital stay (C) and all-cause deathWhat are the clinical implications of our ﬁndings?
Although fatigue is regarded as a cardinal symptom of HF,
its severity does not seem to be routinely recorded judging
by the lack of published reports from clinical trials and
other large datasets. Despite this, smaller studies show it to
be a distressing and disabling as well as common symptom; fatigue 3 occurs while at rest or upon slight exertion. On the composite outcome,
(D).
Figure 3 Outcomes According to Symptom Severity
Dyspnea 1 occurs upon heavy exertion; dyspnea 2 occurs upon moderate exertion; dyspnea 3 occurs when at rest or upon slight exertion. On the composite outcome,
CV death or HF hospital stay (A), CV death (B), HF hospital stay (C), and all-cause death (D).
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194(21–23). Not only that, COMET and CORONA clearly
show that fatigue is an independent predictor of HF hospital
stay, even after adjusting for NYHA class and other
powerful prognostic variables, including NT-proBNP level
(in CORONA). Moreover, CORONA also shows that
worsening fatigue is an adverse prognostic development.
These ﬁndings suggest that closer attention should be paid
to this symptom in clinical practice, that more should
be done to standardize its measurement, and that effort to
understand its origins be intensiﬁed and better treatment
strategies developed. Clearly, there is the possibility that
early detection and treatment of worsening fatigue might
improve outcomes, although this is a hypothesis that needs
to be tested prospectively.
Study limitations. Our study has several limitations. It was
not a prespeciﬁed analysis of the CORONA trial. The pa-
tients enrolled were older subjects with systolic HF of
ischemic origins. A total of 1,181 patients (23.6%) were
excluded from the analyses because patients with an LVEF>35% (and 40%) had to be in NYHA class III or IV, and
we wished to examine the predictive value of fatigue and
dyspnea in addition to NYHA functional class. However,
additional analyses that included these patients gave similar
results. Although our ﬁndings are consistent with those of
COMET and therefore probably can be generalized to most
patients with HF and reduced ejection fraction, we do not
know about the prevalence or prognostic importance of fa-
tigue in patients with HF and preserved ejection fraction.
Fatigue was not measured using a validated score, although
we do not know of any instrument that has been fully vali-
dated in HF and is suitable for use in a large multinational
trial. Because dyspnea was an inclusion criterion in
CORONA, the dyspnea scale had only 4 possible points as
opposed to 5 for fatigue. Subjects were asked about symptoms
over “the past few days,” and these responses were recorded by
investigators. Depression, which is predictive of adverse
events in patients with CV disease, was not measured in
CORONA (24).
Figure 4 CV Death/HF Hospitalization Composite
(A) Outcome is shown according to fatigue level at baseline and NT-proBNP levels at baseline. (B) Outcome is shown according to dyspnea level at baseline and
NT-proBNP levels at baseline.
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In patients with systolic HF, greater fatigue (and an increase
in fatigue) is associated with worse clinical outcomes; the
same is true for dyspnea. Closer attention should be paid tothe symptom of fatigue in clinical practice. More should be
done to standardize its measurement and greater efforts
made to understand its origins. It is possible that an early
therapeutic response to worsening fatigue might reduce
Table 7 Number of Events by Change in Symptoms at 6 Months
Fatigue Dyspnea
Decrease
(n ¼ 712)
Unchanged
(n ¼ 2355)
Increase
(n ¼ 481) p Value
Decrease
(n ¼ 761)
Unchanged
(n ¼ 2420)
Increase
(n ¼ 367) p Value
CV death/HF hospital stay 65/173 (33.4%) 264/627 (37.8%) 50/167 (45.1%) <0.001 76/182 (33.9%) 267/638 (37.4%) 36/147 (49.9%) <0.001
CV death 130 (18.3%) 487 (20.7%) 130 (27.0%) 0.001 141 (18.5%) 506 (20.9%) 100 (27.3%) 0.003
HF hospital stay 173 (24.3%) 627 (26.6%) 167 (34.7%) <0.001 182 (23.9%) 638 (26.4%) 147 (40.1%) <0.001
All-cause death 178 (25.0%) 616 (26.2%) 158 (32.9%) 0.005 192 (25.2%) 635 (26.2%) 125 (34.1%) 0.004
CV ¼ cardiovascular; HF ¼ heart failure.
Table 8 Adjusted Outcomes in Relation to Change in Symptom Severity
CV Death/HF Hospital Stay
HR (95% CI) p Value
Cardiovascular Death
HR (95% CI) p Value
HF Hospital Stay
HR (95% CI) p Value
All-Cause Death
HR (95% CI) p Value
Change in fatigue
Decrease 0.87 (0.73–1.04) 0.14 0.85 (0.67–1.10) 0.22 0.90 (0.73–1.11) 0.34 0.89 (0.72–1.11) 0.31
Increase 1.35 (1.11–1.65) 0.003 1.26 (0.97–1.65) 0.09 1.55 (1.24–1.94) <0.001 1.22 (0.97–1.55) 0.09
Change in dyspnea
Decrease 0.86 (0.72–0.02) 0.08 0.91 (0.7–1.15) 0.41 0.80 (0.65–0.98) 0.04 0.95 (0.77–1.17) 0.62
Increase 1.56 (1.26–1.92) <0.001 1.19 (0.88–1.61) 0.26 1.88 (1.50–2.37) <0.001 1.20 (0.92–1.56) 0.17
*Adjusted for age, sex, New York Heart Association class, left ventricular ejection fraction, body mass index (kg/m2), systolic blood pressure, heart rate, smoking, myocardial infarction, angina pectoris, coronary artery bypass graft, percutaneous coronary intervention, aortic
aneurysm, hypertension, diabetes, baseline atrial ﬁbrillation/ﬂutter, stroke, intermittent claudication, pacemaker, implanted cardioverter-deﬁbrillator, ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, triglycerides, C-reactive protein, high-density lipoproteins,
low-density lipoprotein, estimated glomerular ﬁltration rate.
CV ¼ cardiovascular; HF ¼ heart failure.
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197adverse outcomes in HF, although this hypothesis must be
tested prospectively.Reprint requests and correspondence: Dr. John J. V. McMurray,
Institute of Cardiovascular and Medical Sciences, BHF Glasgow
Cardiovascular Research Centre, University of Glasgow, 126
University Place, Glasgow G12 8TA, Scotland, United Kingdom.
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